BioCentury | Aug 14, 2019
Financial News

Aug. 14 Financial Quick Takes: Biotech tumbles with markets; plus Frontier, Portola and more

Biotech fares better than markets in sell-off U.S. biotech indexes fared slightly better than the broader markets Wednesday as stocks tumbled amid fresh signs of a global economic slowdown and a signal from bond markets...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School 2018: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
BioCentury | Feb 4, 2016
Translation in Brief

Revamped repair

A University of California Berkeley team has discovered how to boost the efficiency of homology-directed repair (HDR) of genomic cuts made by CRISPR- Cas9 , without disrupting proliferation or other DNA repair mechanisms. By dialing in...
BioCentury | Nov 9, 2015
Company News

Direct Genomics sales and marketing update

Direct Genomics launched GenoCare Analyzer in China for genome sequencing of drug-resistant HBV infection and circulating tumor DNA. The assay uses single molecule targeted sequencing to read DNA and RNA molecules from blood or tissue...
BioCentury | Dec 8, 2014
Emerging Company Profile

CRISPR-based therapies

Caribou Biosciences Inc. and Atlas Venture co-founded Intellia Therapeutics LLC to develop gene and cell therapies based on Caribou's CRISPR genome editing technology. Intellia has exclusive rights to CRISPR IP from a co-inventor of the...
BioCentury | Apr 24, 2014
Cover Story

CRISPR in the liver

Despite the fact that the therapeutic utility of CRISPR-based approaches has yet to be demonstrated, venture dollars keep flowing into new companies developing the platform. But proof of concept may come faster than expected as...
BioCentury | May 28, 2009
Distillery Techniques

Technology: Drug platforms

...status Publication and contact information Drug platforms Identification of polyketide biosynthetic pathways in bacteria A structure-directed genomics...
BioCentury | May 22, 2006
Finance

Ebb & Flow

By all accounts, last week was a banner week on the venture side. A total of $175.4 million was raised by private biotechs, which far exceeded the industry’s average of about $100 million per week...
BioCentury | Jan 2, 2006
Company News

Cellectis SA, Shire Pharmaceuticals Group plc deal

Cellectis granted SHP a worldwide, non-exclusive license to use Cellectis' site-directed genome engineering technologies to develop genetically engineered cells that produce gene-activated biopharmaceuticals. Further terms were not disclosed. Cellectis SA , Romainville, France Shire Pharmaceuticals Group...
Items per page:
1 - 9 of 9
BioCentury | Aug 14, 2019
Financial News

Aug. 14 Financial Quick Takes: Biotech tumbles with markets; plus Frontier, Portola and more

Biotech fares better than markets in sell-off U.S. biotech indexes fared slightly better than the broader markets Wednesday as stocks tumbled amid fresh signs of a global economic slowdown and a signal from bond markets...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School 2018: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
BioCentury | Feb 4, 2016
Translation in Brief

Revamped repair

A University of California Berkeley team has discovered how to boost the efficiency of homology-directed repair (HDR) of genomic cuts made by CRISPR- Cas9 , without disrupting proliferation or other DNA repair mechanisms. By dialing in...
BioCentury | Nov 9, 2015
Company News

Direct Genomics sales and marketing update

Direct Genomics launched GenoCare Analyzer in China for genome sequencing of drug-resistant HBV infection and circulating tumor DNA. The assay uses single molecule targeted sequencing to read DNA and RNA molecules from blood or tissue...
BioCentury | Dec 8, 2014
Emerging Company Profile

CRISPR-based therapies

Caribou Biosciences Inc. and Atlas Venture co-founded Intellia Therapeutics LLC to develop gene and cell therapies based on Caribou's CRISPR genome editing technology. Intellia has exclusive rights to CRISPR IP from a co-inventor of the...
BioCentury | Apr 24, 2014
Cover Story

CRISPR in the liver

Despite the fact that the therapeutic utility of CRISPR-based approaches has yet to be demonstrated, venture dollars keep flowing into new companies developing the platform. But proof of concept may come faster than expected as...
BioCentury | May 28, 2009
Distillery Techniques

Technology: Drug platforms

...status Publication and contact information Drug platforms Identification of polyketide biosynthetic pathways in bacteria A structure-directed genomics...
BioCentury | May 22, 2006
Finance

Ebb & Flow

By all accounts, last week was a banner week on the venture side. A total of $175.4 million was raised by private biotechs, which far exceeded the industry’s average of about $100 million per week...
BioCentury | Jan 2, 2006
Company News

Cellectis SA, Shire Pharmaceuticals Group plc deal

Cellectis granted SHP a worldwide, non-exclusive license to use Cellectis' site-directed genome engineering technologies to develop genetically engineered cells that produce gene-activated biopharmaceuticals. Further terms were not disclosed. Cellectis SA , Romainville, France Shire Pharmaceuticals Group...
Items per page:
1 - 9 of 9